Seilern Investment Management Ltd Has $9.77 Million Stock Position in Zoetis Inc. $ZTS

Seilern Investment Management Ltd increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.5% in the second quarter, Holdings Channel reports. The firm owned 62,637 shares of the company’s stock after buying an additional 2,688 shares during the quarter. Zoetis accounts for approximately 0.6% of Seilern Investment Management Ltd’s holdings, making the stock its 18th biggest holding. Seilern Investment Management Ltd’s holdings in Zoetis were worth $9,768,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Portside Wealth Group LLC grew its stake in shares of Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock worth $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. grew its stake in shares of Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after purchasing an additional 198,089 shares during the period. Flagship Harbor Advisors LLC grew its stake in shares of Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock worth $1,217,000 after purchasing an additional 1,760 shares during the period. Horizon Financial Services LLC acquired a new stake in shares of Zoetis during the first quarter worth $380,000. Finally, Sage Rhino Capital LLC grew its stake in shares of Zoetis by 117.6% during the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company’s stock worth $1,155,000 after purchasing an additional 3,791 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZTS. Argus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

Zoetis Stock Performance

Shares of Zoetis stock opened at $148.33 on Friday. The firm has a market cap of $65.74 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89. The stock’s 50-day moving average is $152.32 and its 200-day moving average is $157.26. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.